作者
Magid Awadalla, Doll Lauren Alexandra Golden, Syed S Mahmood, Raza M Alvi, Nathaniel D Mercaldo, Malek ZO Hassan, Dahlia Banerji, Adam Rokicki, Connor Mulligan, Sean PT Murphy, Maeve Jones-O’Connor, Justine V Cohen, Lucie M Heinzerling, Merna Armanious, Ryan J Sullivan, Rongras Damrongwatanasuk, Carol L Chen, Dipti Gupta, Michael C Kirchberger, Javid J Moslehi, Sachin P Shah, Sarju Ganatra, Paaladinesh Thavendiranathan, Muhammad A Rizvi, Gagan Sahni, Alexander R Lyon, Carlo G Tocchetti, Valentina Mercurio, Franck Thuny, Stephane Ederhy, Michael Mahmoudi, Donald P Lawrence, John D Groarke, Anju Nohria, Michael G Fradley, Kerry L Reynolds, Tomas G Neilan
发表日期
2019/12
期刊
Journal for immunotherapy of cancer
卷号
7
页码范围
1-10
出版商
BioMed Central
简介
Background
Influenza vaccination (FV) is recommended for patients with cancer. Recent data suggested that the administration of the FV was associated with an increase in immune-related adverse events (irAEs) among patients on immune checkpoint inhibitors (ICIs). Myocarditis is an uncommon but serious complication of ICIs and may also result from infection with influenza. There are no data testing the relationship between FV and the development of myocarditis on ICIs.
Methods
Patients on ICIs who developed myocarditis (n = 101) (cases) were compared to ICI-treated patients (n = 201) without myocarditis (controls). A patient was defined as having the FV if they were administered the FV from 6 months prior to start of ICI to anytime during ICI therapy. Alternate thresholds for FV status were also tested. The primary comparison of interest was …
学术搜索中的文章
M Awadalla, DLA Golden, SS Mahmood, RM Alvi… - Journal for immunotherapy of cancer, 2019